LONDON, January 25 /PRNewswire/ --

Elertz has launched its widget technology, a patented desktop messaging system which provides online marketers with a new way of communicating with their users and driving website interaction.

The elertz widget is non-intrusive to users and sits in the system tray of their computer waiting quietly for notifications. Critically, end-users are always in complete control of the communication channel and they can manage the information they receive, meaning they are more likely to respond positively to brand marketers who are providing relevant services or innovative products.

LONDON, January 25 /PRNewswire/ -- Clinique is delighted to announce its partnership with Great Ormond Street Hospital for the KISS IT BETTER appeal - to raise money to fund research into the causes and treatment of childhood cancer.

KISS IT BETTER is the brainchild of Carmel Allen whose daughter Josephine was treated at the hospital for Neuroblastoma - a type of cancer. After many months spent at the hospital, and struggling to reconcile life as a Beauty Editor, Carmel decided that she wanted to help and devised the KISS IT BETTER appeal.

KVISTGÅRD, Denmark, January 25 /PRNewswire/ -- Bavarian Nordic announced today that Executive Vice President, Peter Wulff has chosen to seek new challenges outside Bavarian Nordic A/S. He will resign from his position at the end of July 2008 whereupon he will continue as consultant for the company.

Peter Wulff held the position as CEO and President of the company from its inception and until August 2007, where he took over the position as Head of Business Development. The company's success, from its inception and until the commercial breakthrough in 2007, where a large contract with the U.S. government was landed, can largely be attributed to Peter's efforts and contribution.

AACHEN, Germany, January 25 /PRNewswire/ -- The German pain specialist Grunenthal GmbH announces that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for tapentadol immediate release (IR) tablets by its co-development partner Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD). Tapentadol is an oral centrally acting analgesic and will be the first new substance in its class for more than 25 years after successful registration. In the European Union, tapentadol is currently in phase 3 of the development program for severe acute pain, and the Company plans to submit it for approval later this year.

GENEVA, January 24 /PRNewswire/ --

- Effort Focuses on Dangers of Parental Smoking in Homes and Cars

It's a staggering statistic: 700 million children - almost half of the world's youth - breathe air polluted by tobacco smoke. People who smoke in confined spaces like the home or the car subject others to a dangerous mix of toxins including nicotine, carbon monoxide, and cyanide, even when the windows are open. Second-hand smoke exposes children to chronic health risks:

RESEARCH TRIANGLE PARK, North Carolina, January 24 /PRNewswire/ --